Over the past decade, CAR-T therapies have demonstrated curative potential, while also underscoring how complexity, cost, and infrastructure can limit the number of patients who can be treated. In this episode of the Biotech2050 podcast, Artiva’s CEO Fred Aslan discusses how lessons from the first generation of CAR-T therapies are shaping new approaches in autoimmune…
